Cellectis Announces Arbitral Decision in Dispute with Servier

Cellectis, a clinical-stage biotechnology firm specializing in gene editing and cell therapies, recently announced a significant development regarding its legal dispute with Les Laboratoires Servier and Institut de Recherches Internationales Servier IRIS SARL. On December 15, 2025, the company revealed that the Arbitral Tribunal had reached a decision concerning the License, Development, and Commercialization Agreement made in March 2019 between the parties.

The Tribunal ruled for a partial termination of the License Agreement specifically concerning the UCART19 V1 product, also known as ALLO-501, which is associated with Allogene. Furthermore, the Tribunal mandated that Cellectis must engage in discussions with Allogene in good faith to explore potential direct licensing of UCART19 V1. However, all other claims made by both parties in the arbitration were dismissed.

Cellectis is at the forefront of innovative biotechnology, employing an allogeneic approach to CAR T immunotherapies aimed at cancer treatment. Their unique platform allows for the development of ready-to-use, gene-edited CAR T-cells, marking a significant milestone in advancing cancer therapy. With in-house manufacturing capabilities, Cellectis maintains control throughout the entire gene and cell therapy value chain.

Headquartered in Paris and with additional locations in New York and Raleigh, North Carolina, Cellectis is publicly traded on both the Nasdaq Global Market under the ticker CLLS and Euronext Growth under ALCLS. The company continues to focus on creating life-saving treatments based on its pioneering gene-editing technology. For investor and media inquiries, Cellectis has provided contact details in their press release.

Cellectis (NASDAQ: CLLS) has recently undergone a significant event with the Arbitral Tribunal ruling on its dispute with Servier regarding the License, Development, and Commercialization Agreement established in March 2019. The tribunal's decision includes a partial termination of the License Agreement concerning UCART19 V1 (also known as ALLO-501) while requiring Cellectis to engage in discussions about granting a direct license to the product at Allogene’s request.

Given this development, investors should note several critical points. First, the partial termination may provide Cellectis with the opportunity to reposition its strategies surrounding UCART19 V1, allowing the company to strengthen partnerships or explore new avenues for commercialization outside the Servier agreement. Maintaining good-faith discussions indicates a proactive approach to rebuilding relationships in the sector, particularly as Cellectis refines its leverage with Allogene.

From a market perspective, this arbitration ruling may result in short-term volatility in Cellectis' stock price as investors digest the implications. However, Cellectis' pioneering role in gene-editing technology and clinical-stage innovations still positions the company favorably within the burgeoning biotechnology sector. The shift towards allogeneic CAR T therapies is gaining traction, and Cellectis's significant in-house manufacturing capabilities enhance its operational flexibility and market competitiveness.

Investors should consider the long-term fundamentals of Cellectis, focusing on its unique product portfolio, partnerships, and the evolving landscape of gene therapies. Monitoring the company's financial health through future earnings reports and updates on ongoing clinical trials would be prudent for making informed investment decisions.

In conclusion, while the arbitration outcome presents an immediate challenge regarding UCART19, it also opens new pathways for strategic growth. Long-term investors may find this an opportune moment to evaluate Cellectis’ potential in the rapidly advancing gene therapy market.